MONOCLONAL ANTIBODY-BASED TARGETED SEROTHERAPY STRATEGIES AS A NOVEL TREATMENT MODALITY FOR MULTIPLE MYELOMA

Abstract

Several novel immunotherapeutic strategies are being investigated as a current treatment option in Multiple Myeloma (MM), an incurable B-cell malignancy of terminally differentiated plasma cells. Amongst, monoclonal antibodies (MoAbs) -based serotherapy strategies are under preclinical and clinical trials for treating this blood-borne malignancy affecting bone and other end-organs. MoAbs target specific marker proteins in the tumor microenevironment including bone marrow and have been safely administered in cancer patients. This article presents an overview of the clinical implications and therapeutic efficacies of novel MoAbs in MM. It is believed that, ongoing molecular studies and patients’ gene expression profiling would help to identify novel therapeutic targets in myeloma cells for a better prognosis and improved patient outcome in MM.